Acylin Therapeutics
Executives
5Board of Directors
4Acylin Therapeutics Management Team
5 Team Members
Acylin Therapeutics has 5 executives. Acylin Therapeutics's founder is Philip A. Cole. Acylin Therapeutics's is .
Name | Work History | Title | Status |
|---|---|---|---|
Philip A. Cole | Founder | Current | |
Name | Philip A. Cole | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
This profile has not been claimed.
Highlight your management team’s expertise.
Acylin Therapeutics Board of Directors
4 Board of directors
Acylin Therapeutics has 4 board of directors, including Carl Weissman.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
Carl Weissman | Carl Weissman serves concurrently as Chairman and CEO of Accelerator and as a Managing Director at OVP. Carl joined OVP as a Venture Partner in 2007 and became a Managing Director in 2009. He focuses on the digital biology sector, with investments including Allozyne and Fate Therapeutics and Novomer. He is also a Board Observer to Limerick BioPharma, NanoString, Verdezyne and Viral Logic Systems Technology (VLST). Carl led the formation of Accelerator in 2003. Accelerator is a joint investment vehicle backed by a syndicate of venture capital firms, including OVP, which invests in and actively manages emerging biotechnology companies. Accelerator has facilitated Series A investments in, and has managed or is currently managing the operations of five OVP portfolio companies: Allozyne, Seredigm, VLST, GPC-Rx and Mirina. Allozyne and VLST have successfully raised Series B rounds ($55M and $30M respectively) and have "graduated" from Accelerator. Prior to joining OVP, Carl was a Venture Partner at MPM Capital from 2001 through 2006. While at MPM, he served as President and CEO of Centagenetix, a human genetics company in Cambridge, MA. Carl led the 2003 merger of Centagenetix with Elixir Pharmaceuticals, catalyzing a $40M Series B financing in the combined company. Prior to joining MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development. Carl serves on the Board of the Washington Biotechnology and Biomedical Association (WBBA), the Board of the Oregon Translational Research and Drug Development Institute (OTRADI) and is President of the Board of Directors of Teens in Public Service. | Acylin Therapeutics | |
Lee Babiss | Dr. Babiss brings to PPD more than 21 years of experience in developing and leading research and development laboratories. He most recently served as president and director of pharmaceutical research for F. Hoffmann-La Roche, Ltd., in Basel, Switzerland, where his responsibilities included creating global laboratory functions in chemistry, discovery technologies, therapeutic proteins, non-clinical safety and informatics. He supported drug discovery efforts in oncology, neurosciences, inflammation, virology and metabolism and was a member of the company’s pharma executive and strategic portfolios committees. Prior to joining Hoffmann-La Roche, Dr. Babiss spent seven years with Glaxo Inc., now GlaxoSmithKline. As vice president of biological sciences and genetics, he had global accountability for developing and implementing the company’s corporate genetics strategy and oncology research efforts focused on the cell cycle. Dr. Babiss earned a doctorate in microbiology from Columbia University and completed his postdoctoral fellowship at The Rockefeller University, where he served as an assistant and associate professor. He has received numerous fellowship awards and grants and serves on several scientific advisory committees and boards. Mark Esser, Ph.D. | Acylin Therapeutics | |
Steven Gillis | Dr. Steven Gillis is a managing director at ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. In addition to eGenesis, he is also director of Homology Medicines, Inc., Allozyne, Pulmatrix (PULM), Codiak Biosciences, Faraday Pharmaceuticals, Just. Biotherapeutics, VLST, and Accelerator. He serves as director and Chairman of VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines (VBIV), and PhaseRx. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He received a B.A. from Williams College and a Ph.D. from Dartmouth College. | Acylin Therapeutics | |
Thong Le | Thong Q. Le currently serves as Senior Managing Director and CEO of Accelerator. Mr. Le has over 20 years of experience identifying, investing in, managing, and successfully exiting numerous seed and early-stage investments in the biotechnology sector. He has served as the founding CEO and director of numerous Accelerator Life Science Partners portfolio companies, including Petra Pharma (substantial acquisition by a global pharmaceutical company in May 2020), Rodeo Therapeutics (acquired by Amgen Inc. for up to $721 million in March 2021), and Lodo Therapeutics (acquired by Zymergen in May 2021). He currently oversees the firm’s investments in ALSP ORCHID Acquisition Corporation I (NASDAQ: ALORU | ALOR), Lydian Neurosciences, Magnolia Neurosciences, and Proniras Corporation, where he also serves as CEO and Director of each company. Prior to joining Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation where he played a significant role in the early sourcing, financing, and development of numerous life science companies, including Alder Biopharmaceuticals (NASDAQ: ALDR | acquired by H. Lundbeck A/S), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO), Hyperion Therapeutics (NASDAQ: HPTX | acquired by Horizon Pharma plc), Lumera (NASDAQ: LMRA), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures. Mr. Le completed post-graduate studies at the Templeton College of Oxford University and received his A.B. cum laude in Government from Harvard University. He serves on the advisory board for the Alexandria Seed Capital Platform and on the boards of Acylin Therapeutics, Briotech, and Ravenna Pharmaceuticals. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal. | Acylin Therapeutics |
Name | Carl Weissman | Lee Babiss | Steven Gillis | Thong Le |
|---|---|---|---|---|
Firm | ||||
Work History | Carl Weissman serves concurrently as Chairman and CEO of Accelerator and as a Managing Director at OVP. Carl joined OVP as a Venture Partner in 2007 and became a Managing Director in 2009. He focuses on the digital biology sector, with investments including Allozyne and Fate Therapeutics and Novomer. He is also a Board Observer to Limerick BioPharma, NanoString, Verdezyne and Viral Logic Systems Technology (VLST). Carl led the formation of Accelerator in 2003. Accelerator is a joint investment vehicle backed by a syndicate of venture capital firms, including OVP, which invests in and actively manages emerging biotechnology companies. Accelerator has facilitated Series A investments in, and has managed or is currently managing the operations of five OVP portfolio companies: Allozyne, Seredigm, VLST, GPC-Rx and Mirina. Allozyne and VLST have successfully raised Series B rounds ($55M and $30M respectively) and have "graduated" from Accelerator. Prior to joining OVP, Carl was a Venture Partner at MPM Capital from 2001 through 2006. While at MPM, he served as President and CEO of Centagenetix, a human genetics company in Cambridge, MA. Carl led the 2003 merger of Centagenetix with Elixir Pharmaceuticals, catalyzing a $40M Series B financing in the combined company. Prior to joining MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development. Carl serves on the Board of the Washington Biotechnology and Biomedical Association (WBBA), the Board of the Oregon Translational Research and Drug Development Institute (OTRADI) and is President of the Board of Directors of Teens in Public Service. | Dr. Babiss brings to PPD more than 21 years of experience in developing and leading research and development laboratories. He most recently served as president and director of pharmaceutical research for F. Hoffmann-La Roche, Ltd., in Basel, Switzerland, where his responsibilities included creating global laboratory functions in chemistry, discovery technologies, therapeutic proteins, non-clinical safety and informatics. He supported drug discovery efforts in oncology, neurosciences, inflammation, virology and metabolism and was a member of the company’s pharma executive and strategic portfolios committees. Prior to joining Hoffmann-La Roche, Dr. Babiss spent seven years with Glaxo Inc., now GlaxoSmithKline. As vice president of biological sciences and genetics, he had global accountability for developing and implementing the company’s corporate genetics strategy and oncology research efforts focused on the cell cycle. Dr. Babiss earned a doctorate in microbiology from Columbia University and completed his postdoctoral fellowship at The Rockefeller University, where he served as an assistant and associate professor. He has received numerous fellowship awards and grants and serves on several scientific advisory committees and boards. Mark Esser, Ph.D. | Dr. Steven Gillis is a managing director at ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. In addition to eGenesis, he is also director of Homology Medicines, Inc., Allozyne, Pulmatrix (PULM), Codiak Biosciences, Faraday Pharmaceuticals, Just. Biotherapeutics, VLST, and Accelerator. He serves as director and Chairman of VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines (VBIV), and PhaseRx. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He received a B.A. from Williams College and a Ph.D. from Dartmouth College. | Thong Q. Le currently serves as Senior Managing Director and CEO of Accelerator. Mr. Le has over 20 years of experience identifying, investing in, managing, and successfully exiting numerous seed and early-stage investments in the biotechnology sector. He has served as the founding CEO and director of numerous Accelerator Life Science Partners portfolio companies, including Petra Pharma (substantial acquisition by a global pharmaceutical company in May 2020), Rodeo Therapeutics (acquired by Amgen Inc. for up to $721 million in March 2021), and Lodo Therapeutics (acquired by Zymergen in May 2021). He currently oversees the firm’s investments in ALSP ORCHID Acquisition Corporation I (NASDAQ: ALORU | ALOR), Lydian Neurosciences, Magnolia Neurosciences, and Proniras Corporation, where he also serves as CEO and Director of each company. Prior to joining Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation where he played a significant role in the early sourcing, financing, and development of numerous life science companies, including Alder Biopharmaceuticals (NASDAQ: ALDR | acquired by H. Lundbeck A/S), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO), Hyperion Therapeutics (NASDAQ: HPTX | acquired by Horizon Pharma plc), Lumera (NASDAQ: LMRA), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures. Mr. Le completed post-graduate studies at the Templeton College of Oxford University and received his A.B. cum laude in Government from Harvard University. He serves on the advisory board for the Alexandria Seed Capital Platform and on the boards of Acylin Therapeutics, Briotech, and Ravenna Pharmaceuticals. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal. |
Other Seats | Acylin Therapeutics | Acylin Therapeutics | Acylin Therapeutics | Acylin Therapeutics |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.